An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
NCT ID: NCT03692897
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
1708 participants
OBSERVATIONAL
2018-10-11
2025-09-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
NCT01671787
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
NCT03982186
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
NCT03753074
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
NCT05005507
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
NCT03471624
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
All approved therapies for the treatment of Chronic Hepatitis B (CHB).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Being managed for chronic hepatitis B (CHB), including patients who have achieved functional cure and patients with concurrent delta hepatitis
Exclusion
1. Inability to provide written informed consent
2. Known history of Human Immunodeficiency Virus (HIV)
3. History of liver transplantation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Target PharmaSolutions, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner University Medical Center Phoenix
Phoenix, Arizona, United States
Asian Pacific Liver Center at Coalition of Inclusive Medicine
Los Angeles, California, United States
California Liver Research Institute
Pasadena, California, United States
Stanford University
Redwood City, California, United States
UC Davis GI/Hepatology Clinical Trials Unit
Sacramento, California, United States
Silicon Valley Research Institute
San Jose, California, United States
Yale University Digestive Diseases
New Haven, Connecticut, United States
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
University of Florida
Gainesville, Florida, United States
University of Miami, Schiff Center for Liver Disease
Miami, Florida, United States
Consultative Gastroenterology
Atlanta, Georgia, United States
Atlanta Gastroenterology
Atlanta, Georgia, United States
Rush Universtiy Medical Center
Chicago, Illinois, United States
University of Chicago
Chicago, Illinois, United States
Mercy Medical Center
Baltimore, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Minnesota Gastroenterology, P.A.
Plymouth, Minnesota, United States
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Dreamwork Medical, PLLC
Flushing, New York, United States
Northwell Health Center for Liver Diseases and Transplantation
Manhasset, New York, United States
NYU Langone Health
New York, New York, United States
Weill Cornell Medical College
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
UNC Liver Center
Chapel Hill, North Carolina, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Digestive and Liver Disease Specialist
Norfolk, Virginia, United States
Bon Secours Liver Institute of Richmond
Richmond, Virginia, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Swedish Organ Transplant and Liver Center
Seattle, Washington, United States
University of Washington/Harborview Medical Center
Seattle, Washington, United States
UHN Toronto General Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bernstein DE, Trinh HN, Schiff ER, Smith CI, Mospan AR, Zink RC, Fried MW, Lok AS. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV. Dig Dis Sci. 2022 Jun;67(6):2637-2645. doi: 10.1007/s10620-021-07033-y. Epub 2021 May 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TARGET-HBV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.